SOLO Microbiome - Services to understand its role | Oncodesign

Microbiome

Microbiome insights

 

 

Over the past decade, research has revealed that the human microbiome (with bacteria as the most numerous members) plays an important role in human health and in the treatment of human diseases.

Even if the causality is not always established, a microbial imbalance or dysbiosis has been reported in several diseases including gastrointestinal and dermal diseases, metabolic disorders, CNS pathologies and cancer. Furthermore, the microbiome has been shown to influence the efficacy of immunotherapy and chemotherapeutic agents or to metabolize drugs.

The understanding and the evaluation of the role of the microbiome in the discovery and development of new therapeutic molecules is currently of high interest. Microbiome is clearly a key player in drug development process.

Oncodesign Services has developed translational skills and experience in this growing field to serve the evolving needs of R&D programs in oncology immuno-oncology, inflammatory diseases infectious diseases including Covid-19, dermocosmetics and nutrition.

 

 

Microbiome - Non-exhaustive list of pathologies related to microbiome disorders

Non-exhaustive list of pathologies related to microbiome disorders

Tackling the microbiome in drug discovery

Several topics of interest have emerged in microbiome research leading:

  • To study the relationship between microbiome composition and the disease of interest
  • To define the role of microbiome in precision diagnosis and personalized treatment
  • To develop and evaluate microbiome therapeutics
  • To understand the impact of a drug on microbiome and the influence of microbiome on individual’s response to a drug

Oncodesign Services has developed a comprehensive offer giving our customers access to technologic and scientific expertise, platforms and networks with the purpose to support their project i.e. to demonstrate the benefit on health, to assess safety and/or to decipher mechanism(s) of action of microbiome-based therapeutics or non-microbial drugs.

 

A fully integrated microbiome platform for preclinical studies

Microbiome - A fully integrated microbiome platform for preclinical studies

A wide range of distinct and diversified services

Our facilities, environment and collaborations/networks allow Oncodesign Services to work with preclinical and clinical samples (GLP/GcLP compliant environment in bioanalysis) and to manipulate live microorganisms (BSL2, BSL3 and GMO2 compliant laboratories).

Models & Readouts

Oncodesign Services proposes tools suitable for mimicking healthy and pathological situations, studying interplay with immune system for screening purpose and proof of concept.

  • Experimental approaches
    • In vitro 2D & 3D co-cultures
    • SPF/SOPF, germ-free animals or with a custom microbiota
    • Human biological specimen
  • Immune phenotyping
    • Cytokine profile
    • Immune infiltrate
  • Biomarkers
    • Gut permeability (e.g. zonulin)
    • Inflammation (e.g. calprotectin, lipocalin-2)
    • Metabolites (e.g. short-chain fatty acids)

Methods & Analyses

Oncodesign Services offers a broad range of technological approaches for culturing, detecting, identifying and localizing microorganisms (bacteria, yeasts, etc.) in simple or complex samples (fluids, tissues) coming from preclinical studies or clinical trials.

  • Culture / Formulation
    • Culture of aerobic or anaerobic bacteria and yeasts
    • Preparation of single strain or consortium (with quality control of batches)
    • Handling of wild type, engineered microbes or derivatives
    • Formulation of frozen, lyophilized, pasteurized products
  • Detection
    • CFU counting
    • qPCR coupled or not to PMA
  • Identification
    • Mass spectrometry
    • qPCR/dPCR
    • 16S rRNA gene sequencing
    • Shotgun sequencing
    • Phylopeptidomics
  • Localization
    • Imaging
    • Ex vivo culture

 

Microbiome - Schéma: Models & Readouts + Methods & Analyses

Microbiome case studies

Our multidisciplinary team designs tailor-made studies for evaluating microbiome-based therapeutics and drug-microbiome interactions.

Discover hereafter few examples of experiments conducted at Oncodesign:

  • The extent to which treatment with chemotherapeutic agents could impact gut microbiota composition.
  • Whether bacteria could rescue the efficacy of an immune checkpoint inhibitor in avatar mice.
  • Would a live biotherapeutic product modulate immune responses in intestinal tissue and tumor microenvironment?
  • Could induced colitis be treated with fecal microbiota transplantation?
  • Could atopic dermatitis be alleviated by a single strain?
  • Use of PMA-qPCR/-dPCR as a valuable method to enable quantification of live bacteria in clinical samples (feces, skin swabs).

 

Example #1 : Profile of microbiome studies and axes of interest

Profile of microbiome studies and axes of interest.

Example #2 :Selective colonization of a subcutaneous tumor by IV administered bacteria

 

Microbiome - Selective colonization of a subcutaneous tumor by IV administered bacteria

Example #3 : Gut decontamination by a cocktail of antibiotics (ATB) prior transfer of fecal material (FMT) in healthy mice

 

Microbiome - Gut decontamination by a cocktail of antibiotics (ATB) prior transfer of fecal material (FMT) in healthy mice

Example #4 : Impact of a chemotherapeutic agent on gut microbiome composition in tumor-bearing mice

 

Microbiome - Impact of a chemotherapeutic agent on gut microbiome composition in tumor-bearing mice

Example #5 :Metabolization of a pro-drug by gut microbiota to prevent inflammation in a mouse model of colitis

Microbiome - Metabolization of a pro-drug by gut microbiota to prevent inflammation in a mouse model of colitis

Our microbiome network

Getting to the heart of Oncodesign Services ecosystem made of:

logo-biofortis_200px

 

Biofortis

A specialist in microbiome analysis.

VIVEXIA_logo

 

 

Vivexia

An expert in microbiology.

logo-medicen-200px

Medicen

A health innovation hub as coordinator of the Microbiome Drug Metabolism Working Group (members: national and international academic groups, biotechnology and pharmaceutical companies, CROs and regulatory affairs).